Akums Drugs and Pharmaceuticals' shares began trading at Rs 725, a 6.8% premium over the issue price of Rs 679, after an IPO that was subscribed 63.5 times. The company will use the IPO proceeds for debt repayment, working capital, and acquisitions. Revenue grew 14% in FY24, while profits saw a decline.